Clinical and prognostic significance of combined plasma fibrinogen concentrations and the monocyte-to-lymphocyte ratio in patients with ovarian cancer.
Ovarian cancer
fibrinogen concentration
monocyte-to-lymphocyte ratio (MLR)
Journal
Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
entrez:
19
7
2019
pubmed:
19
7
2019
medline:
19
7
2019
Statut:
ppublish
Résumé
Fibrinogen concentrations and the monocyte-to-lymphocyte ratio (FC-MLR) are associated with progression and outcomes of many malignancies. This study aimed to assess the clinical and prognostic significance of the combination of plasma FC-MLR in patients with ovarian cancer. A total of 155 patients with epithelial ovarian cancer (EOC) and 102 patients with benign gynecological disease were retrospectively reviewed. The clinical and pathological data of all patients with EOC were analyzed. Plasma fibrinogen concentrations and the white blood cell (WBC) count were measured to calculate the MLR and neutrophil-to-lymphocyte ratio (NLR). Furthermore, the association of fibrinogen concentrations, the MLR, and FC-MLR with tumor stage, lymphatic and venous metastasis, and 5-year survival was assessed. Regression analysis was performed to evaluate the risk factors for progression of EOC. Receiver operating characteristic (ROC) curves were constructed to assess the prognostic power of plasma fibrinogen concentrations, the MLR, and FC-MLR, and to determine the optimal cutoff values of fibrinogen and the MLR. On the basis of the cutoff values, patients with EOC were divided into three groups: no abnormality, either increased, and both increased groups, respectively. The effect of FC-MLR on overall survival was calculated by the Kaplan-Meier method and compared by the log-rank test in the three groups. Patients with EOC had higher fibrinogen concentrations and a higher MLR than did controls (both P<0.01), and FC-MLR was closely associated with tumor stage and lymphatic and venous metastasis (all P<0.001). Furthermore, FC-MLR was an independent risk factor for progression of EOC (OR =8.985; 95% CI: 4.912-27.166; P<0.001), and patients with high fibrinogen concentrations and a high MLR showed a lower 5-year survival rate (P<0.001). FC-MLR may be used as a predictor of tumor progression and prognosis for ovarian cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Fibrinogen concentrations and the monocyte-to-lymphocyte ratio (FC-MLR) are associated with progression and outcomes of many malignancies. This study aimed to assess the clinical and prognostic significance of the combination of plasma FC-MLR in patients with ovarian cancer.
METHODS
METHODS
A total of 155 patients with epithelial ovarian cancer (EOC) and 102 patients with benign gynecological disease were retrospectively reviewed. The clinical and pathological data of all patients with EOC were analyzed. Plasma fibrinogen concentrations and the white blood cell (WBC) count were measured to calculate the MLR and neutrophil-to-lymphocyte ratio (NLR). Furthermore, the association of fibrinogen concentrations, the MLR, and FC-MLR with tumor stage, lymphatic and venous metastasis, and 5-year survival was assessed. Regression analysis was performed to evaluate the risk factors for progression of EOC. Receiver operating characteristic (ROC) curves were constructed to assess the prognostic power of plasma fibrinogen concentrations, the MLR, and FC-MLR, and to determine the optimal cutoff values of fibrinogen and the MLR. On the basis of the cutoff values, patients with EOC were divided into three groups: no abnormality, either increased, and both increased groups, respectively. The effect of FC-MLR on overall survival was calculated by the Kaplan-Meier method and compared by the log-rank test in the three groups.
RESULTS
RESULTS
Patients with EOC had higher fibrinogen concentrations and a higher MLR than did controls (both P<0.01), and FC-MLR was closely associated with tumor stage and lymphatic and venous metastasis (all P<0.001). Furthermore, FC-MLR was an independent risk factor for progression of EOC (OR =8.985; 95% CI: 4.912-27.166; P<0.001), and patients with high fibrinogen concentrations and a high MLR showed a lower 5-year survival rate (P<0.001).
CONCLUSIONS
CONCLUSIONS
FC-MLR may be used as a predictor of tumor progression and prognosis for ovarian cancer.
Identifiants
pubmed: 31317012
doi: 10.21037/atm.2019.04.78
pii: atm-07-11-242
pmc: PMC6603346
doi:
Types de publication
Journal Article
Langues
eng
Pagination
242Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Blood. 2000 Dec 1;96(12):3772-8
pubmed: 11090059
Adv Protein Chem. 2005;70:247-99
pubmed: 15837518
Blood. 2007 Mar 1;109(5):1971-4
pubmed: 17082318
J Thromb Haemost. 2008 Jan;6(1):176-83
pubmed: 17949478
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Obstet Gynaecol Res. 2012 Apr;38(4):651-7
pubmed: 22413879
Int J Gynaecol Obstet. 2014 Jan;124(1):1-5
pubmed: 24219974
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
pubmed: 25559415
BMC Cancer. 2016 Jan 27;16:43
pubmed: 26817451
Mediators Inflamm. 2016;2016:3494608
pubmed: 26941482
Transl Oncol. 2017 Feb;10(1):33-39
pubmed: 27888711
J Gynecol Oncol. 2017 May;28(3):e36
pubmed: 28382799
Medicine (Baltimore). 2017 Apr;96(17):e6694
pubmed: 28445272
PLoS One. 2017 Aug 24;12(8):e0182383
pubmed: 28837575
Obstet Gynecol Sci. 2017 Nov;60(6):558-564
pubmed: 29184864
Cell Physiol Biochem. 2018;45(3):951-961
pubmed: 29428948
FEBS J. 2018 Feb;285(4):638-640
pubmed: 29479848
Int J Gynecol Cancer. 2018 Jun;28(5):939-944
pubmed: 29538251
J Cancer. 2018 Mar 8;9(7):1127-1134
pubmed: 29675093
Turk J Obstet Gynecol. 2018 Sep;15(3):177-181
pubmed: 30202628
Cancer Manag Res. 2018 Sep 12;10:3433-3450
pubmed: 30254487
BMC Cancer. 2018 Oct 3;18(1):943
pubmed: 30285763
BMC Gastroenterol. 2018 Oct 11;18(1):148
pubmed: 30305076
J Cancer. 2018 Oct 10;9(21):3904-3911
pubmed: 30410594
Acta Oncol. 1995;34(1):69-73
pubmed: 7532422
Jpn J Clin Oncol. 1998 Dec;28(12):740-4
pubmed: 9879291